Atlas Venture
Edit

Atlas Venture

http://www.atlasventure.com
Last activity: 15.01.2025
Active
Invests in categories: BioTechDrugDevelopmentHealthTechPlatformMedtechProductTechnologyPublicResearch
Portfolio
73
Persons
9
Mentions
247
Employees: 11-50
Investment Stage: Seed; Series A; Series B

Portfolio 73

DateNameWebsiteTotal RaisedLocation
19.07.2024GRO Biosci...grobio.com$87.4MCanada, On...
26.10.2023Aiolos Bioaiolosbio.com$245MUnited Sta...
26.10.2023Triveni Bi...triveni.bio$207MUnited Sta...
15.06.2023AAVantgard...aavantgardebio.com-Italy, Lom...
18.12.2022Mariana On...marianaoncology.com$175MUnited Sta...
18.12.2022Viela Biohorizontherapeutics.com$23MUnited Sta...
16.10.2022Matchpoint...matchpointtx.com$100MUnited Sta...
03.10.2022Pheon Ther...pheontx.com$120MUnited Kin...
18.05.2022Remix Ther...remixtx.com$211MUnited Sta...
20.04.2022Sionna The...sionnatx.com$293MUnited Sta...
Show more

Persons 9

DateFirst NameLast NameTitleLinkedInLocation
-MichaelGladstonePartner-
-BruceBoothDPhil, Par...-
-JasonRhodesPartner-
-AlisonButtsReceptioni...linkedin.c...-
-PeterBarrettPhD, Partn...-
-AimeeRaleighPhD, Princ...linkedin.c...-
-Jean-Franç...FormelaMD, Partne...-
-JuliaPianMD, Associ...linkedin.c...-
-AndreaDiMellaVice Presi...linkedin.c...-

Mentions in press and media 247

DateTitleDescription
15.01.2025Be Bio Closes $92M Series C FinancingBe Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding. The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,...
14.12.2024The Rise of nChroma Bio: A New Dawn in Genetic MedicineIn the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g...
12.12.2024Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio and Raises $75MBiotechnology companies Chroma Medicine (Boston, MA) and Nvelop Therapeutics (Cambridge, MA) announced their merger and subsequent launch of nChroma Bio to expand the R&D of the genetic medicines sector. Concurrent with the merger, nChr...
08.12.2024Atlas Venture: $450 Million Fund XIV Closed To Invest In Biotech InnovationAtlas Venture—a leading early-stage venture capital firm investing in biotech innovation—announced closing its fourteenth fund, raising $450 million in an oversubscribed fundraise. Through Fund XIV, Atlas Venture will continue collaborating...
13.11.2024Trace Neuroscience: A New Dawn in Genomic Medicine for ALSIn the realm of biopharmaceuticals, a new player has emerged, armed with ambition and a hefty $101 million in Series A funding. Trace Neuroscience is on a mission to reshape the landscape of genomic medicine, particularly for those grapplin...
13.11.2024Trace Neuroscience: $101 Million (Series A) Raised To Expand Genomic Medicine PlatformTrace Neuroscience – a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases – announced its launch with a $101 million Series A funding led by Third Rock Ventures, with partic...
28.10.2024Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New FundingIn the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn...
25.10.2024Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell MedicinesBe Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo...
07.10.2024Kailera Therapeutics: $400 Million (Series A) Raised To Advance Next-Gen Therapies For ObesityKailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for treating obesity and related conditions. And Kailera launches with a $400 million...
04.10.2024Triveni Bio: $115 Million (Series B) Closed To Advance Novel Antibody Treatments For I&I DisordersTriveni Bio, a biotech company advancing novel antibody treatments for I&I disorders, announced a $115 million Series B to support pipeline expansion. The funding round was led by Goldman Sachs Alternatives with significant participatio...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In